Drug Development

Adjuvant Drug Helps Eradicates Cancer Cells In Solid Tumors

Published in Cancer Weekly, August 14th, 2001

BTG (BGC) announced the start of a Phase I clinical study to test AQ4N, a new drug designed to increase the effectiveness of several widely used anticancer drugs as well as radiotherapy.

This clinical study, funded by BTG and organized by the U.K.'s Cancer Research Campaign, will take place at Leicester Royal Infirmary and Imperial Cancer Research Fund's unit at the Churchill Hospital, Oxford, United Kingdom. The study should provide a good foundation for further trials of the efficacy of AQ4N in a range of tumor types when given with radiotherapy or with cancer chemotherapeutics.

The main objectives of the trial are to establish the maximum...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Cancer Weekly

Source: Cancer Weekly (2001-08-14)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry